newsfilter
← Earnings
Earnings Releases·

Beam Therapeutics — Third Quarter 2026 Earnings Summary

  • Net loss widened to $134.4 million ($1.28/share) in Q3 2026 from $112.6 million ($1.10/share) in Q3 2025, driven by a 16% year-over-year increase in total operating expenses to $141.6 million and a sharp decline in license revenue to $0.3 million from $9.7 million.
  • Cash and marketable securities decreased to $1.0 billion as of September 30, 2026, from $1.2 billion at year-end 2025, though the company projects a runway extending to mid-2029 contingent on drawing an additional $200 million from its Sixth Street credit facility.
  • Key clinical milestones include an expected U.S. BLA submission for risto-cel by year-end 2026, completion of dosing for the BEAM-302 pivotal cohort in H1 2027, and initiation of BEAM-304 Phase 1/2 trials in early 2027.
  • Strategic updates include the appointment of Eric Foster as chief commercial officer in September and the identification of next-generation targeted lipid nanoparticles for hematopoietic stem cell delivery in advanced lead optimization.
Company
BEAM THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology